Article
Biochemistry & Molecular Biology
Lara Samadan, Neven Papic, Maja Mijic, Ivana Knezevic Stromar, Slavko Gasparov, Adriana Vince
Summary: This study aimed to identify semaphorins associated with nonalcoholic fatty liver disease (NAFLD) and their relationship with steatosis and fibrosis stages. The findings showed that certain semaphorins were associated with fibrosis in NAFLD patients and had better accuracy in predicting fibrosis compared to the FIB-4 score.
Review
Cardiac & Cardiovascular Systems
Alessandro Mantovani, Christopher D. Byrne, Giovanni Benfari, Stefano Bonapace, Tracey G. Simon, Giovanni Targher
Summary: There is a strong association between nonalcoholic fatty liver disease (NAFLD) and heart failure (HF), with higher severity of NAFLD being associated with an increased risk of new-onset HF. Patients with NAFLD may develop accelerated coronary atherosclerosis, myocardial alterations, and certain arrhythmias, which may precede and promote the development of HF.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2022)
Review
Gastroenterology & Hepatology
Richie Manikat, Mindie H. Nguyen
Summary: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease characterized by excess fat accumulation in the liver. It is associated with metabolic syndrome and often presents with comorbidities such as obesity, type 2 diabetes mellitus, and dyslipidemia. NAFLD is also linked to non-liver comorbidities including cardiovascular disease, chronic kidney disease, and sleep apnea. Managing these comorbidities is crucial for improving liver-related and overall health outcomes in patients with NAFLD.
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Article
Medicine, General & Internal
Yun Hwan Oh, Seogsong Jeong, Sun Jae Park, Joseph C. Ahn, Sang Min Park
Summary: The changes in NAFLD status are associated with the risk of cardiovascular disease (CVD), with an increased risk observed in patients who develop NAFLD and a reduced risk in individuals who recover from NAFLD.
Article
Biochemistry & Molecular Biology
Laia Bertran, Rosa Jorba-Martin, Andrea Barrientos-Riosalido, Marta Portillo-Carrasquer, Carmen Aguilar, David Riesco, Salome Martinez, Margarita Vives, Fatima Sabench, Daniel Del Castillo, Cristobal Richart, Teresa Auguet
Summary: This study found that OLFMs play a relevant role in NAFLD-related intestinal dysbiosis, with OLFMs in the liver potentially influencing the progression of NAFLD and OLFMs in the jejunum potentially being involved in gut dysbiosis-related inflammatory events.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Young-Sun Lee, Ji Eun Lee, Hyon-Seung Yi, Young Kul Jung, Dae Won Jun, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Baek-hui Kim, Jeong Woo Kim, Chang Hee Lee, Jong Eun Yeon, Juneyoung Lee, Soon Ho Um, Kwan Soo Byun
Summary: This study aimed to develop a scoring system for the diagnosis of nonalcoholic steatohepatitis (NASH) using multiparametric magnetic resonance (MR) and clinical indicators. The MRE-based NASH score showed satisfactory accuracy in diagnosing NASH in patients with nonalcoholic fatty liver disease (NAFLD).
HEPATOLOGY INTERNATIONAL
(2022)
Review
Endocrinology & Metabolism
Jeanne M. M. Clark, Donna R. H. Cryer, Michelle Morton, Jay H. H. Shubrook
Summary: Nonalcoholic fatty liver disease (NAFLD) affects a large portion of the US population, with a significant number of patients progressing to nonalcoholic steatohepatitis (NASH) which increases the risk of liver-related complications and mortality. NASH is also associated with other metabolic comorbidities, adverse cardiovascular outcomes, and extrahepatic cancers. Early diagnosis of NAFLD is crucial in preventing progression to NASH, but it is often underdiagnosed. This review focuses on the clinical impact of NASH and provides practical guidance on its diagnosis and management for primary care providers, using case studies to illustrate real-world scenarios encountered in the primary care setting.
DIABETES OBESITY & METABOLISM
(2023)
Review
Immunology
Wenhui Zhang, Ren Lang
Summary: NAFLD and NASH are significant contributors to liver disease worldwide. Macrophages play a crucial role in the pathogenesis of NAFLD and NASH, and their metabolic characteristics influence their activation state and functionality. Targeting macrophage metabolism could be a promising therapeutic approach for the management of NAFLD/NASH.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Gastroenterology & Hepatology
Dong Hyun Sinn, Danbee Kang, Sung Chul Choi, Yun Soo Hong, Di Zhao, Eliseo Guallar, Yewan Park, Juhee Cho, Geum-Youn Gwak
Summary: The clinical implications of nonalcoholic fatty liver disease (NAFLD) in subjects who fulfill the diagnostic criteria of metabolic (dysfunction)-associated fatty liver disease (MAFLD) are unknown.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Kara Wegermann, Marat Fudim, Ricardo Henao, Catherine F. Howe, Robert McGarrah, Cynthia Guy, Manal F. Abdelmalek, Anna Mae Diehl, Cynthia A. Moylan
Summary: This study aimed to identify serum metabolites associated with heart failure with preserved ejection fraction (HFpEF) in patients with nonalcoholic fatty liver disease (NAFLD), and to identify common mechanisms. The findings showed increased levels of multiple lipid metabolites in the serum of HFpEF patients, suggesting that lipid metabolism could be an important pathway linking HFpEF to NAFLD.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)
Review
Gastroenterology & Hepatology
Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee
Summary: The transition from NAFLD to MAFLD involves including FLD subjects with metabolic abnormalities in the criteria while excluding those without, leading to a focus on metabolic dysfunction in the MAFLD criteria. This may underestimate the prognostic value of hepatic steatosis, but could better identify subjects at higher risk of liver or cardiovascular outcomes.
CLINICAL AND MOLECULAR HEPATOLOGY
(2021)
Article
Endocrinology & Metabolism
Ningning You, Jiali Xu, Liyan Wang, Lili Zhuo, Jingxin Zhou, Yu Song, Aliaweis Ali, Yan Luo, Jin Yang, Wenjun Yang, Minghua Zheng, Jing Xu, Li Shao, Junping Shi
Summary: The study found that there are significant differences in the gut fungal structure of NAFLD patients, and some fungi may be associated with NAFLD development, liver injury, and lipid metabolism. Therefore, research on gut fungi may have important value for diagnosing and monitoring NAFLD.
Review
Cell Biology
Amila Iriskic Atic, Maja Thiele, Alexander Munk, Louise Torp Dalgaard
Summary: MicroRNAs (miRNAs) secreted by the liver have the potential to be important biomarkers for nonalcoholic liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Several miRNAs, including miR-122, miR-21, miR-34a, miR-192, miR-193, and the miR-17-92 miRNA-cluster, are consistently associated with NAFLD/NASH. These miRNAs show potential as diagnostic markers for NAFLD/NASH, although more research is needed to understand their specificity and regulation.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
(2023)
Review
Food Science & Technology
Jing-Wen Yang, Hong-Fang Ji
Summary: Phytosterols are bioactive food components found in plant cell membranes, especially in nuts and oilseeds. Many studies have shown their therapeutic potential for nonalcoholic fatty liver disease (NAFLD). They lower total cholesterol and triglyceride levels through various mechanisms and improve NAFLD.
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
(2023)
Review
Biochemistry & Molecular Biology
Julia A. Golubeva, Anna F. Sheptulina, Anastasia Yu. Elkina, Ekaterina O. Liusina, Anton R. Kiselev, Oxana M. Drapkina
Summary: Non-alcoholic fatty liver disease (NAFLD) and arterial hypertension (AH) are common non-communicable diseases worldwide. They often coexist and are associated with each other regardless of the presence of other metabolic factors.
Review
Gastroenterology & Hepatology
Leonard Depotte, Juliette Palle, Cosimo Rasola, Chloe Broudin, Vlad-Adrian Afrasanie, Antoine Mariani, Aziz Zaanan
Summary: Advanced gastric adenocarcinoma is a disease with poor prognosis. In recent years, new drugs, such as trastuzumab for HER2-positive tumors, ramucirumab alone or in combination with paclitaxel, and trifluridine-tipiracil, have improved patient survival. Other drugs, including monoclonal antibodies and targeted therapies, are also being evaluated.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
(2024)
